Westwood Holdings Group Inc. Purchases 400 Shares of GlaxoSmithKline PLC (NYSE:GSK)
Westwood Holdings Group Inc. boosted its stake in GlaxoSmithKline PLC (NYSE:GSK) by 15.7% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 2,950 shares of the pharmaceutical company’s stock after buying an additional 400 shares during the period. Westwood Holdings Group Inc.’s holdings in GlaxoSmithKline PLC were worth $124,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in GSK. PVG Asset Management Corp purchased a new position in shares of GlaxoSmithKline PLC during the first quarter valued at approximately $4,138,000. Sterling Investment Advisors Ltd. boosted its position in shares of GlaxoSmithKline PLC by 9.0% in the first quarter. Sterling Investment Advisors Ltd. now owns 25,900 shares of the pharmaceutical company’s stock valued at $1,092,000 after buying an additional 2,145 shares during the last quarter. Endurant Capital Management LP boosted its position in shares of GlaxoSmithKline PLC by 52.4% in the first quarter. Endurant Capital Management LP now owns 131,700 shares of the pharmaceutical company’s stock valued at $5,552,000 after buying an additional 45,300 shares during the last quarter. Paloma Partners Management Co boosted its stake in GlaxoSmithKline PLC by 31.3% in the first quarter. Paloma Partners Management Co now owns 13,002 shares of the pharmaceutical company’s stock valued at $549,000 after buying an additional 3,102 shares in the last quarter. Finally, National Asset Management Inc. boosted its stake in GlaxoSmithKline PLC by 3.7% in the first quarter. National Asset Management Inc. now owns 54,712 shares of the pharmaceutical company’s stock valued at $2,308,000 after buying an additional 1,948 shares in the last quarter. Institutional investors own 8.96% of the company’s stock.
GlaxoSmithKline PLC (GSK) traded down 0.15% during trading on Thursday, hitting $40.69. 2,898,645 shares of the stock were exchanged. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $45.21. The stock has a market cap of $100.07 billion, a price-to-earnings ratio of 40.13 and a beta of 1.03. The firm’s 50 day moving average price is $42.68 and its 200-day moving average price is $41.84.
GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, analysts anticipate that GlaxoSmithKline PLC will post $2.84 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be given a $0.491 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.83%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 194.00%.
Several analysts recently commented on GSK shares. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a report on Monday, April 17th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, April 25th. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. BNP Paribas upgraded shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and decreased their price target for the stock from $45.58 to $37.20 in a report on Wednesday, April 5th. Finally, Exane BNP Paribas upgraded shares of GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating in a report on Wednesday, April 5th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the stock. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and a consensus price target of $46.00.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.